This story was originally published March 8.

Despite the increasingly competitive noninvasive prenatal testing market, Sequenom said that sales of its MaterniT21 Plus test have continued to grow, and were key in more than doubling the firm's revenues in the fourth quarter of 2012 over those of the previous year's quarter.

The company finished the quarter with $33.7 million in revenue, a 117 percent increase from its fourth quarter 2011 revenues of $15.5 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.